Why the autophagy-lysosomal pathway became Parkinson’s primary disease-modification target

Parkinson’s disease is driven by two interconnected failures: the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, and the collapse of cellular protein quality-control machinery — specifically lysosomal hydrolases, autophagy receptors, and mitophagy effectors — that normally prevent α-synuclein from accumulating into the Lewy bodies that characterise the disease. Understanding this second failure has transformed drug discovery strategy. Where early PD therapeutics focused on replacing lost dopamine, the current pipeline is increasingly aimed at restoring the cellular clearance mechanisms that, when intact, prevent the neurodegeneration from occurring in the first place.

The genetic architecture of PD has made the autophagy-lysosomal pathway (ALP) impossible to ignore as a therapeutic target. Pathogenic variants in GBA1 (encoding lysosomal glucocerebrosidase), LRRK2 (a kinase that phosphorylates Rab GTPases controlling lysosomal trafficking), PINK1, and Parkin/PARK2 (the mitophagy axis) all converge on the same cellular machinery. The result is a feedforward loop: reduced lysosomal GCase activity allows α-synuclein to accumulate, which further impairs lysosomal function, which allows more α-synuclein to accumulate. Breaking this loop — rather than managing its downstream consequences — is the defining ambition of the current generation of lysosomal-autophagy targeting therapies.

The targets most prominently represented across retrieved patent and literature records are: GBA1/GCase, LRRK2, PINK1/Parkin/MIRO1, Rab1a (microautophagy), TFEB/ZKSCAN3 (lysosomal biogenesis), Parkin/PARIS/PGC-1α (mitochondrial-lysosomal biogenesis), autophagy execution genes ATG3, ATG7, and GABARAPL2, and c-Abl kinase (Parkin preservation). Each of these represents a distinct entry point into the ALP, and the pipeline now includes small molecules, gene therapy vectors, and novel GTPase-based approaches targeting all of them. According to WIPO, patent filings in neurodegenerative disease mechanisms have accelerated substantially over the past decade, consistent with the breadth of activity observed in this dataset.

Nine therapeutic modalities targeting lysosomal-autophagy biology in PD

The patent dataset reveals nine distinct mechanistic approaches to restoring ALP function in Parkinson’s disease, ranging from the most clinically advanced (GCase activation) to genuinely novel preclinical strategies (Rab1a^GDP microautophagy enhancement) with no competitive prior art in older filings.

1. GCase activators — the nearest-term lysosomal opportunity

BIAL–R&D Investments S.A. holds the most recent and targeted lysosomal-specific filings in this dataset: two pending patents (IL 2025, JP 2026) claiming 5,7-dimethyl-N-((1R,4R)-4-(pentyloxy)cyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Compound A) for GBA-PD patients with confirmed low GCase activity. These filings explicitly acknowledge the failure of venglustat (benglurastat) in the MOVES-PD Phase 2 trial — a substrate reduction therapy that did not slow motor progression — and position direct GCase enzyme activation as the next-generation response. Patient eligibility is defined by GCase enzyme activity level measured as a pharmacodynamic criterion, and motor progression is the primary endpoint, language consistent with Phase 2 clinical protocol design.

“Treatment with microautophagy enhancers comprising the GDP-bound form of Rab1a can be used to reduce cell death in individuals affected by Parkinson’s disease” — a mechanism with no competitive prior art in the older patent literature, prosecuted across at least six international jurisdictions.

2. LRRK2 kinase inhibitors — the broadest IP estate

LRRK2 inhibition is the most IP-developed kinase approach in this dataset. LRRK2 gain-of-function mutations such as G2019S cause hyperphosphorylation of Rab GTPases including Rab8A and Rab10, leading to lysosomal fragmentation and impaired autophagic flux. Oncodesign S.A. describes macrocyclic LRRK2 inhibitors for PD and Alzheimer’s disease; Denali Therapeutics’ pending JP filing focuses on treatment monitoring via kinase pharmacodynamic readouts; and Neuron23’s filing extends inhibitor eligibility beyond the approximately 1–2% of PD patients carrying gain-of-function LRRK2 mutations to sporadic PD patients identified through genetic modifier profiling of wild-type LRRK2 activity — a strategically significant patient population expansion. The Medical Research Council filing identifies the ERM (ezrin/radixin/moesin) family as LRRK2 substrates and describes the GTPase, COR, and kinase domains as essential for pathological function.

3. Rab1a^GDP microautophagy enhancement — a high-novelty unencumbered space

The most mechanistically distinctive innovation cluster in this dataset centres on GDP-bound Rab1a (Rab1a^GDP) as an activator of microautophagy. Rab1a is a small GTPase ordinarily involved in ER-to-Golgi trafficking; filings from Reliable Holdings Co., Ltd. (operating as Motigenix Singapore Pte. Ltd.) propose that its GDP-locked mutant forms — including Rab1a^S25N, Rab1a^N124I, Rab1a^D41N, and Rab1a^D47N — paradoxically activate microautophagy, the direct engulfment of cytosolic proteins by lysosomes, bypassing the macroautophagic initiation complex entirely. The filings state explicitly that treatment with microautophagy enhancers comprising the GDP-bound form of Rab1a can be used to reduce cell death in individuals affected by Parkinson’s disease. Active international prosecution across WO, AU, TW, KR, JP, and CN jurisdictions signals an aggressive early-stage IP strategy with no competitive filings from other assignees retrievable in this dataset.

4. PKC pathway activation of lysosomal biogenesis (TFEB/GCase co-induction)

Cedars-Sinai Medical Center’s filings disclose PKC activators — including DAG, phorbol esters, bryostatin, ingenol, and indolactam compounds — as agents that simultaneously modulate TFEB and ZKSCAN3, the reciprocal transcriptional regulators of lysosomal gene networks, alongside GCase and α-synuclein levels in iPSC-derived dopaminergic neurons. TFEB (transcription factor EB) and ZKSCAN3 operate in opposition on the same promoter network: TFEB activates lysosomal biogenesis genes while ZKSCAN3 represses them. PKC activation tips this balance toward biogenesis, coupling lysosomal expansion with dopaminergic neuroprotection in a patient-derived cellular model system.

5–9. Mitophagy, gene therapy, c-Abl, PARIS/PGC-1α, and lysosomal enzyme strategies

Stanford University’s MIRO1-reducing agent filings connect LRRK2^G2019S mutations to MIRO1 stabilization on damaged mitochondria, suppressing mitophagy initiation — and propose companion diagnostics based on MIRO protein levels. Rocket Pharmaceuticals’ gene therapy filing encodes PARK2, PINK1, ATG7, GBA, DJ-1, LRRK2, SNCA, c-Rel, and VMAT2 alongside CRISPR/Cas approaches in a single patent claim set, directly linking autophagy execution and lysosomal enzyme function as co-targets. Ariad Pharmaceuticals (now Takeda) holds multiple — now inactive — filings on BBB-penetrant c-Abl inhibitors that preserve Parkin E3 ubiquitin ligase activity by preventing tyrosine-143 phosphorylation; Sun Pharmaceutical Advanced Research’s 2025 CN filing on vodobatinib adds a more recent entry to c-Abl inhibition in early PD. Johns Hopkins University’s PARIS/PGC-1α farnesylation filings describe farnesol-mediated de-repression of PGC-1α transcription to restore mitochondrial biogenesis and the lysosomal gene network, supported by NIH grant NS38377. The General Hospital Corporation (Massachusetts General Hospital) holds an active JP patent describing broader lysosomal activation strategies for proteinopathies including α-synuclein accumulation.

Who is building this pipeline: assignee and IP landscape

Patent activity in this dataset is predominantly driven by a mix of clinical-stage biotechs, academic medical centres with active licensing programs, and emerging platform companies pursuing novel mechanisms. The landscape is geographically distributed, with filings active across IL, JP, CN, AU, KR, TW, WO, CA, and ES jurisdictions — reflecting both the global nature of the PD patient population and the strategic importance of securing IP in major pharmaceutical markets.

BIAL–R&D Investments S.A. (Portugal) holds the most recent and targeted lysosomal filings, with two pending patents directed specifically at GBA-PD patients and a biomarker-defined patient selection strategy that signals a clinical-stage program. Cedars-Sinai Medical Center (USA) contributes multiple filings on iPSC-derived dopaminergic neuron platforms and PKC-pathway lysosomal activation. Reliable Holdings / Motigenix prosecutes Rab1a^GDP across WO, AU, TW, KR, JP, and CN — a breadth and recency (2024–2026) indicating an early-stage but internationally aggressive IP strategy. Johns Hopkins University’s PARIS/PGC-1α farnesylation filings carry NIH-funded academic origins and appear in JP and KR jurisdictions. Stanford University’s MIRO1 filings include a companion diagnostic component that distinguishes this program from purely therapeutic IP. Rocket Pharmaceuticals’ gene therapy vector claims span PARK2, PINK1, ATG7, GBA, and CRISPR approaches in a single JP pending application. Denali Therapeutics holds a JP pending filing consistent with its known clinical programs in lysosomal-autophagy PD biology. Ariad Pharmaceuticals (now Takeda) holds multiple inactive 2013-era filings on BBB-penetrant c-Abl inhibitors — no currently active Ariad filings appear in this dataset.

Clinical and translational signals: how close are these approaches to patients?

Several retrieved results carry specific clinical translation signals that allow approximate staging assessments — though all are derived from patent language rather than verified clinical trial registrations, and should be interpreted accordingly.

BIAL’s Compound A filings reference the MOVES-PD Phase 2 clinical trial failure of venglustat and describe motor progression endpoints alongside patient populations defined by DaT SPECT-confirmed PD and GBA1 pathogenic variants — language consistent with Phase 2 clinical protocol design. One filing states that patients “have been diagnosed with clinically probable PD” per MDS clinical diagnostic criteria, indicating enrollment-ready patient definition. Sun Pharmaceutical Advanced Research’s 2025 CN filing for vodobatinib in early PD references DaT SPECT, skin punch biopsy for abnormal synuclein deposition, and MDS clinical diagnostic criteria, specifying that subjects “have been initially diagnosed within 3 years of beginning treatment” — a planned early-intervention design. AskBio’s JP filing describes a transduction threshold of at least 30% of putamen volume and a 6-month observation period as success criteria — language consistent with Phase 1/2 gene therapy trial design.

Cedars-Sinai’s iPSC platform — validated in patient-derived iPSC neurons with clinical data linkage — provides a translational bridge rather than a clinical intervention. The University of Nebraska’s GM-CSF biomarker patent describes a patient selection algorithm using autophagy gene expression levels of ATG3, ATG7, and GABARAPL2 alongside neuroinflammation markers, implying integration of autophagy flux biomarkers into a clinical treatment decision framework. According to NIH, biomarker-stratified trial designs have become increasingly standard in neurodegenerative disease research, a trend reflected in the precision medicine orientation of multiple filings in this dataset. The European Medicines Agency has similarly emphasised patient stratification and companion diagnostic co-development as key requirements for disease-modification claims in neurodegenerative indications.

Combination strategies and the precision medicine turn

The retrieved results signal a clear directional shift: from single-target symptomatic therapy toward combination approaches that address multiple nodes of the ALP simultaneously, selected by molecular biomarkers that match mechanism to patient biology.

Several convergent strategies are apparent. First, GCase activation and α-synuclein clearance are increasingly viewed as synergistic — BIAL’s filings and the General Hospital Corporation’s lysosomal activation patent both embed lysosomal enzyme enhancement within a broader aggregate clearance framework, addressing both the cause (lysosomal failure) and the consequence (α-synuclein accumulation) simultaneously. Second, Stanford’s MIRO1 filing explicitly connects LRRK2^G2019S to MIRO1 stabilization, indicating that LRRK2 inhibitors may restore mitophagy flux as a downstream mechanism — suggesting potential for LRRK2 inhibitor plus mitophagy enhancer combinations to be rationally designed. Third, Rocket Pharmaceuticals’ claim set encoding PARK2, PINK1, ATG7, and GBA within a single patent application signals interest in combinatorial gene delivery restoring multiple nodes of the lysosomal-autophagy pathway simultaneously. Fourth, the Rab1a^GDP filings explicitly note that microautophagy “bypasses” macroautophagic machinery, suggesting that this approach may complement macroautophagy-dependent strategies such as TFEB activation in patients where upstream autophagy initiation is dysfunctional.

“Multiple recent filings integrate specific molecular biomarkers — GCase activity, ATG3/ATG7 expression, LRRK2 genetic modifiers — into treatment eligibility criteria, signalling a shift toward precision medicine trials in lysosomal-autophagy PD.”

The precision medicine turn is most visible in the biomarker-stratified patient selection strategies now embedded in clinical-language filings. BIAL uses GCase enzyme activity level as a pharmacodynamic criterion; the University of Nebraska proposes ATG3, ATG7, and GABARAPL2 expression as autophagy flux biomarkers; and Neuron23 uses LRRK2 genetic modifier profiling to extend inhibitor eligibility to sporadic PD patients with wild-type LRRK2 — expanding the addressable patient population beyond the approximately 1–2% of PD patients with gain-of-function LRRK2 mutations. Stanford’s MIRO1 filings include companion diagnostic claims based on MIRO protein levels. This convergence of mechanism-specific biomarkers with clinical trial design is consistent with the broader trend toward precision neurology described by Nature and supported by regulatory frameworks at the FDA for companion diagnostic co-development. From a strategic standpoint, the Rab1a^GDP / microautophagy space remains unencumbered by competitive filings in this dataset, and the LRRK2 inhibitor landscape — while dense — is being extended by Neuron23’s wild-type LRRK2 patient population strategy. Gene therapy vectors incorporating ATG7 and GBA represent a high-risk, high-reward convergence of autophagy execution and lysosomal enzyme function as co-targets in CNS gene therapy.